Travere Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Okay. Good morning, and welcome to day 2 of the Barclays Global Healthcare Conference.
My name is Carter Gould, Senior Biopharma Analyst here at Barclays, and it's my pleasure to welcome Travere Therapeutics up next.
Representing the company is CEO, Eric Dube. The company is really entering what we've called a defining period over the next, call it, 6 to 9 months. We recently initiated on Travere and they've had some positive data. Their key drug sparsentan in an initial indication and are engaging with regulators and other studies on the horizon. So with that, Eric, welcome, and thank you for joining us today.
Absolutely. Thank you, Carter, and thank you to Barclays for hosting us today.
We were just talking before it's fitting with World Kidney Day set for tomorrow.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |